Frequently Asked Questions

Biopharma Partners
  1. How does Predicine help with biomarker discovery in clinical trials and translational research?

    Predicine’s expertise in genomic profiling can help to identify elusive cancer-related genetic changes and new biomarker targets across many cancer types.  The proprietary GeneRADAR technology is able to identify all classes of cancer variants including TMB, MSI, HRD, and gene deletion. 

  2. How can working with Predicine facilitate drug development?

    Predicine offers a liquid biopsy next-generation sequencing (NGS) assay with the potential to incorporate multiple companion diagnostic (CDx) markers into one test.  The CDx co-development model can help our biopharma partners accelerate drug development timeline and facilitate CDx & drug approval.

  3. Do you test clinical trial samples from US, EU and China?

    Yes. Patient samples collected at trial sites in US, EU, and APAC are tested and analyzed at Predicine’s laboratory in Hayward, California. Patient samples collected at trial sites in China are tested and analyzed at Predicine’s laboratory in Shanghai, China.

  4. Which phases of clinical trials do you support?

    Predicine works with leading biopharmas to support global clinical trials from Phase I to III. 

  5. What services does Predicine offer for biopharmaceutical companies?

    Predicine partners with biopharmaceutical companies to help accelerate biomarker-driven drug development – from target discovery to commercial launch. We provide comprehensive genomic profiling and molecular insights to assist Biopharmas in translational research, clinical trials, and launch.

  1. What lab licenses and accreditations does Predicine have?

    Predicine’s laboratories are CLIA-certified and CAP-accredited. See Predicine’s list of certifications here.

  2. What is comprehensive genomic profiling?

    Comprehensive genomic profiling is a tumor testing method that enables the detection of multiple oncology biomarkers that help optimize treatment in a single next-generation sequencing test. Predicine performs comprehensive genomic profiling on multiple sample types including blood, urine, and tissue to test for all types of genomic alterations, including mutations, copy number variants (amplification and loss), splice variants, and fusions (rearrangements), associated with targeted therapy opportunities for a panel of cancer associated genes.

  3. What type of CLIA assays does Predicine offer to support treatment selection?


  4. Who is eligible for the test?

    Any patient with a solid tumor or sarcoma is eligible for our tests.

  5. How is the test result provided?

    Test results will be reported in a patient report.

  6. How to order a test?

    All tests must be ordered by a licensed and registered physician or other qualified healthcare provider. Place your order by filling out this form.

  1. Where is Predicine’s laboratory located?

    Predicine has CLIA-certified and CAP-accredited laboratories in the US and China.
    US: 3555 Arden Road, Hayward, California, 94545, USA
    China: 1698 Wangyuan Road, Building 11, Shanghai, 201499, China

  2. What is Predicine lab’s hours of operation?

    Predicine’s lab is open from Monday to Friday from 9:00 AM – 5:00 PM PST.

  3. What specimen types are accepted and what are the specimen requirements?
    Plasma (2 – 4 ml)
    Urine (40 ml)
    Whole blood (4 – 10 ml)
    FFPE (10 slides; 25 mm² surface size; 20% tumor content)

  4. What is the turnaround time?

    10 days.

  5. Are Predicine assays CLIA-certified or RUO?

    Predicine offers both CLIA-certified assays and RUO assays.

Get in touch

If you have any questions that isn’t answered above, you can also contact us using the form below and we will follow up by email within 24 hours.